Inclinix Announces Expansion
Inclinix, Inc., a contract research organization (CRO) specializing in clinical trial enrollment solutions, announces the expansion of its in-field Regional Recruitment Manager (RRM) team, including international and multi-lingual professionals.
Inclinix Announces Expansion of Regional Recruitment Manager Enrollment Support Team
WILMINGTON, N.C., Oct. 15 /PRNewswire/-Inclinix, Inc., a contract research organization (CRO) specializing in clinical trial enrollment solutions, announces the expansion of its in-field Regional Recruitment Manager (RRM) team, including international and multi-lingual professionals. In response to the emergent demand for enrollment experts in the field to assist with difficult to enroll studies, Inclinix has increased the team by 200%.
Regional Recruitment Managers are enrollment experts, clinically experienced across multiple therapeutic areas and trained to develop and execute site-specific patient recruitment strategies. These professionals identify patient recruitment opportunities and challenges both within the site and its adjacent community. In addition to providing hands-on resources to site staff to identify potential study participants, RRMs serve an important role in the continuing education and promotion of studies within healthcare networks supporting and surrounding the site. This unique outreach drives study participation while educating healthcare providers and other patient advocates.
Tobin Geatz, President and CEO of Inclinix says, "the industry is demanding new and innovative strategies to solve the day-to-day challenges of patient recruitment." Geatz further states, "our sponsors know our reputation as experts in patient recruitment, and have easily adopted our Regional Recruitment Managers as a solution to make their sites more productive."
Regional Recruitment Managers are critical to successful enrollment, particularly in trials requiring special populations, low incidences of disease, or in difficult-to-enroll trials where traditional recruitment tactics may be less effective. In a recent study of a special population, RRMs increased enrollment by 60% over sites not supported with RRMs. On average, sites supported with RRMs exceed monthly screening goals and contribute to successful enrollment milestones.
Inclinix clients have benefited from successful programs in therapeutic areas including congestive heart failure, pediatric hypertension,
post-operative pain and pre-term labor. With the expanded Regional Recruitment Manager team, Inclinix will steadily pursue enrollment challenges that cannot be met by traditional patient recruitment methods.
About Inclinix
Inclinix, Inc. is a CRO specializing in customized Phase I-IV clinical trial enrollment solutions for global pharmaceutical, biotechnology, and medical device organizations. Clients benefit from ten years of experience in multiple therapeutic areas, as well as leading edge technologies that meet the challenge of clinical development from feasibility through compliance. In addition, Inclinix provides strategic medical marketing communications and adherence services to the healthcare industry.
For more information, visit www.inclinix.com.
SOURCE Inclinix, Inc.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
